Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib

Wen Hsin Chang, Ta Chih Liu, Wen Kuang Yang, Chien Chih Lee, Yi Hsiung Lin, Tsai Yun Chen, Jan Gowth Chang

研究成果: Article

46 引文 (Scopus)

摘要

The antihypertensive drug amiloride is being considered as a tactic to improve cancer therapy including that for chronic myelogenous leukemia. In this study, we show that amiloride modulates the alternative splicing of various cancer genes, including Bcl-x, HIPK3, and BCR/ABL, and that this effect is not mainly related to pH alteration, which is a known effect of the drug. Splice modulation involved various splicing factors, with the phosphorylation state of serine-arginine-rich (SR) proteins also altered during the splicing process. Pretreatment with okadaic acid to inhibit protein phosphatase PP1 reversed partially the phosphorylation levels of SR proteins and also the amiloride-modulated yields of Bcl-xs and HIPK3 U(-) isoforms. Genome-wide detection of alternative splicing further revealed that many other apoptotic genes were regulated by amiloride, including APAF-1, CRK, and SURVIVIN. Various proteins of the Bcl-2 family and MAPK kinases were found to be involved in amiloride-induced apoptosis. Moreover, the effect of amiloride on mRNA levels of Bcl-x was demonstrated to translate to the protein levels. Cotreatment of K562 and BaF3/Bcr-AblT315I cells with amiloride and imatinib induced more loss of cell viability than either agent alone. Our findings suggest that amiloride may offer a potential treatment option for chronic myelogenous leukemia either alone or in combination with imatinib.

原文English
頁(從 - 到)383-392
頁數10
期刊Cancer Research
71
發行號2
DOIs
出版狀態Published - 2011 一月 15

指紋

Amiloride
Alternative Splicing
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serine
Arginine
Proteins
MAP Kinase Kinase 2
Phosphorylation
Okadaic Acid
Imatinib Mesylate
Neoplasm Genes
Phosphoprotein Phosphatases
Antihypertensive Agents
Cell Survival
Protein Isoforms
Genome
Apoptosis
Messenger RNA
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

引用此文

Chang, Wen Hsin ; Liu, Ta Chih ; Yang, Wen Kuang ; Lee, Chien Chih ; Lin, Yi Hsiung ; Chen, Tsai Yun ; Chang, Jan Gowth. / Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. 於: Cancer Research. 2011 ; 卷 71, 編號 2. 頁 383-392.
@article{371ffccefb25454983a3fb29ca61ae83,
title = "Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib",
abstract = "The antihypertensive drug amiloride is being considered as a tactic to improve cancer therapy including that for chronic myelogenous leukemia. In this study, we show that amiloride modulates the alternative splicing of various cancer genes, including Bcl-x, HIPK3, and BCR/ABL, and that this effect is not mainly related to pH alteration, which is a known effect of the drug. Splice modulation involved various splicing factors, with the phosphorylation state of serine-arginine-rich (SR) proteins also altered during the splicing process. Pretreatment with okadaic acid to inhibit protein phosphatase PP1 reversed partially the phosphorylation levels of SR proteins and also the amiloride-modulated yields of Bcl-xs and HIPK3 U(-) isoforms. Genome-wide detection of alternative splicing further revealed that many other apoptotic genes were regulated by amiloride, including APAF-1, CRK, and SURVIVIN. Various proteins of the Bcl-2 family and MAPK kinases were found to be involved in amiloride-induced apoptosis. Moreover, the effect of amiloride on mRNA levels of Bcl-x was demonstrated to translate to the protein levels. Cotreatment of K562 and BaF3/Bcr-AblT315I cells with amiloride and imatinib induced more loss of cell viability than either agent alone. Our findings suggest that amiloride may offer a potential treatment option for chronic myelogenous leukemia either alone or in combination with imatinib.",
author = "Chang, {Wen Hsin} and Liu, {Ta Chih} and Yang, {Wen Kuang} and Lee, {Chien Chih} and Lin, {Yi Hsiung} and Chen, {Tsai Yun} and Chang, {Jan Gowth}",
year = "2011",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-10-1037",
language = "English",
volume = "71",
pages = "383--392",
journal = "Cancer Research",
issn = "0008-5472",
number = "2",

}

Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. / Chang, Wen Hsin; Liu, Ta Chih; Yang, Wen Kuang; Lee, Chien Chih; Lin, Yi Hsiung; Chen, Tsai Yun; Chang, Jan Gowth.

於: Cancer Research, 卷 71, 編號 2, 15.01.2011, p. 383-392.

研究成果: Article

TY - JOUR

T1 - Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib

AU - Chang, Wen Hsin

AU - Liu, Ta Chih

AU - Yang, Wen Kuang

AU - Lee, Chien Chih

AU - Lin, Yi Hsiung

AU - Chen, Tsai Yun

AU - Chang, Jan Gowth

PY - 2011/1/15

Y1 - 2011/1/15

N2 - The antihypertensive drug amiloride is being considered as a tactic to improve cancer therapy including that for chronic myelogenous leukemia. In this study, we show that amiloride modulates the alternative splicing of various cancer genes, including Bcl-x, HIPK3, and BCR/ABL, and that this effect is not mainly related to pH alteration, which is a known effect of the drug. Splice modulation involved various splicing factors, with the phosphorylation state of serine-arginine-rich (SR) proteins also altered during the splicing process. Pretreatment with okadaic acid to inhibit protein phosphatase PP1 reversed partially the phosphorylation levels of SR proteins and also the amiloride-modulated yields of Bcl-xs and HIPK3 U(-) isoforms. Genome-wide detection of alternative splicing further revealed that many other apoptotic genes were regulated by amiloride, including APAF-1, CRK, and SURVIVIN. Various proteins of the Bcl-2 family and MAPK kinases were found to be involved in amiloride-induced apoptosis. Moreover, the effect of amiloride on mRNA levels of Bcl-x was demonstrated to translate to the protein levels. Cotreatment of K562 and BaF3/Bcr-AblT315I cells with amiloride and imatinib induced more loss of cell viability than either agent alone. Our findings suggest that amiloride may offer a potential treatment option for chronic myelogenous leukemia either alone or in combination with imatinib.

AB - The antihypertensive drug amiloride is being considered as a tactic to improve cancer therapy including that for chronic myelogenous leukemia. In this study, we show that amiloride modulates the alternative splicing of various cancer genes, including Bcl-x, HIPK3, and BCR/ABL, and that this effect is not mainly related to pH alteration, which is a known effect of the drug. Splice modulation involved various splicing factors, with the phosphorylation state of serine-arginine-rich (SR) proteins also altered during the splicing process. Pretreatment with okadaic acid to inhibit protein phosphatase PP1 reversed partially the phosphorylation levels of SR proteins and also the amiloride-modulated yields of Bcl-xs and HIPK3 U(-) isoforms. Genome-wide detection of alternative splicing further revealed that many other apoptotic genes were regulated by amiloride, including APAF-1, CRK, and SURVIVIN. Various proteins of the Bcl-2 family and MAPK kinases were found to be involved in amiloride-induced apoptosis. Moreover, the effect of amiloride on mRNA levels of Bcl-x was demonstrated to translate to the protein levels. Cotreatment of K562 and BaF3/Bcr-AblT315I cells with amiloride and imatinib induced more loss of cell viability than either agent alone. Our findings suggest that amiloride may offer a potential treatment option for chronic myelogenous leukemia either alone or in combination with imatinib.

UR - http://www.scopus.com/inward/record.url?scp=78751562185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751562185&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1037

DO - 10.1158/0008-5472.CAN-10-1037

M3 - Article

C2 - 21224352

AN - SCOPUS:78751562185

VL - 71

SP - 383

EP - 392

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -